Ola Landgen, MD, PhD

Ever-Expanding Indications for Daratumumab in MM

Practical Management of IV Daratumumab in MM

Exciting Subcutaneous Formulation Approval in MM

Clinical Impact of SubQ Daratumumab for Multiple Myeloma

The Impact of COVID-19 on Patients With Multiple Myeloma

Videos

How the recent FDA approval of the subcutaneous formulation of daratumumab in multiple myeloma will affect patients and oncologists from practical and clinical standpoints.

Role of Novel Subcutaneous Daratumumab in Multiple Myeloma

Ola Landgren, MD, PhD, head of the Myeloma Service, Memorial Sloan Kettering Cancer Center, professor of Medicine, Cornell Medical College, on the progression treatments from combinations toward three-drug treatments and the use of monoclonal antibodies. Landgen adds that while he does have faith that monoclonal antibodies will change the treatment landscape in oncology, he says they could very well be combined with old and new drugs.

Landgren says his hopes for three-drug treatments are mainly for the treatment of patients with "high risk" disease, he says they could also be useful in other risk types. Landgren cites the ASPIRE trial published in New England Journal Medicine, saying patients in the trial who received carfilzomib, lenalidomide, and dexamethasone gained an extra 10 months of progression-free survival.

Ola Landgren, MD, PhD, on the progression treatments from combinations toward three-drug treatments and the use of monoclonal antibodies. Landgen adds that while he does have faith that monoclonal antibodies will change the treatment landscape in oncology, he says they could very well be combined with old and new drugs.

Ola Landgen, MD, PhD | Authors

Articles

Role of Novel Subcutaneous Daratumumab in Multiple Myeloma

Dr. Ola Landgren on Three-Drug Treatments and the Use of Monoclonal Antibodies